New drug offers hope for chronic stomach pain and nausea

NCT ID NCT05621811

Completed Symptom relief Sponsor: Dr. Falk Pharma GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called naronapride in 328 adults with moderate to severe gastroparesis (stomach paralysis). Participants took either 10, 20, or 40 mg of the drug or a placebo daily for 12 weeks. The goal was to see if the drug could reduce symptoms like nausea, vomiting, and bloating better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus gastroparesis idiopathic gastroparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROPARESIS

Contacts and locations

Locations

Dr Falk Investigational Site

Chula Vista, California, 91910, United States
Dr Falk Investigational Site

Lomita, California, 90717, United States
Dr Falk Investigational Site

Clearwater, Florida, 33756, United States
Dr Falk Investigational Site

Doral, Florida, 33126, United States
Dr Falk Investigational Site

Hollywood, Florida, 33021, United States
Dr Falk Investigational Site

Maitland, Florida, 32751, United States
Dr Falk Investigational Site

Miami, Florida, 33144, United States
Dr Falk Investigational Site

Miami, Florida, 33183, United States
Dr Falk Investigational Site

Viera, Florida, 32940, United States
Dr Falk Investigational Site

Topeka, Kansas, 66606, United States
Dr Falk Investigational Site

Crestview Hills, Kentucky, 41017, United States
Dr Falk Investigational Site

Houma, Louisiana, 70363, United States
Dr Falk Investigational Site

Marrero, Louisiana, 70072, United States
Dr Falk Investigational Site

Flint, Michigan, 48439, United States
Dr Falk Investigational Site

Flint, Michigan, 48503, United States
Dr Falk Investigational Site

New York, New York, 10033, United States
Dr Falk Investigational Site

Tulsa, Oklahoma, 74104, United States
Dr Falk Investigational Site

Philadelphia, Pennsylvania, 19087, United States
Dr Falk Investigational Site

Cordova, Tennessee, 38018, United States
Dr Falk Investigational Site

Nashville, Tennessee, 37211, United States
Dr Falk Investigational Site

Harlingen, Texas, 78550, United States
University of Leuven

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.